Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
APLT Applied Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: APLT
Price (delayed)
$0.384
Market cap
$54.37M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.28
Enterprise value
$6.3M
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company's lead drug candidate,
Highlights
The company's EPS has surged by 85% YoY and by 63% QoQ
The company's net income has surged by 78% YoY and by 59% QoQ
The company's gross profit has surged by 156% YoY but it fell by 42% QoQ
APLT's revenue has surged by 156% year-on-year but it is down by 42% since the previous quarter
The equity has declined by 46% year-on-year and by 36% since the previous quarter
Key stats
What are the main financial stats of APLT
Market
Valuations
Earnings
Shares outstanding
141.58M
Market cap
$54.37M
Enterprise value
$6.3M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.22
Price to sales (P/S)
209.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.7
Revenue
$266,000
Gross profit
$266,000
Operating income
-$108.73M
Net income
-$43.51M
EBIT
-$43.51M
EBITDA
-$43.1M
Free cash flow
-$94.03M
Per share
Balance sheet
Liquidity
EPS
-$0.28
EPS diluted
-$0.43
Free cash flow per share
-$0.65
Book value per share
$0.32
Revenue per share
$0
TBVPS
$0.39
Total assets
$56.91M
Total liabilities
$20.24M
Debt
$2.7M
Equity
$36.67M
Working capital
$36M
Debt to equity
0.07
Current ratio
3
Quick ratio
2.83
Net debt/EBITDA
1.12
Margins
Efficiency
Dividend
EBITDA margin
-16,203.4%
Gross margin
100%
Net margin
-16,357.5%
Operating margin
-40,875.9%
Return on assets
-46.1%
Return on equity
-101.2%
Return on invested capital
N/A
Return on capital employed
-111.7%
Return on sales
-16,357.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APLT stock price
How has the Applied Therapeutics stock price performed over time
Intraday
5.55%
1 week
8.69%
1 month
-5.63%
1 year
-91.47%
YTD
-55.15%
QTD
-21.46%
Financial performance
How have Applied Therapeutics's revenue and profit performed over time
Revenue
$266,000
Gross profit
$266,000
Operating income
-$108.73M
Net income
-$43.51M
Gross margin
100%
Net margin
-16,357.5%
The company's gross profit has surged by 156% YoY but it fell by 42% QoQ
APLT's revenue has surged by 156% year-on-year but it is down by 42% since the previous quarter
The company's net income has surged by 78% YoY and by 59% QoQ
The operating margin has plunged by 78% from the previous quarter
Price vs fundamentals
How does APLT's price correlate with its fundamentals
Growth
What is Applied Therapeutics's growth rate over time
Valuation
What is Applied Therapeutics stock price valuation
P/E
N/A
P/B
1.22
P/S
209.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.7
The company's EPS has surged by 85% YoY and by 63% QoQ
APLT's price to book (P/B) is 97% less than its last 4 quarters average of 44.1 and 92% less than its 5-year quarterly average of 14.8
The equity has declined by 46% year-on-year and by 36% since the previous quarter
APLT's revenue has surged by 156% year-on-year but it is down by 42% since the previous quarter
Efficiency
How efficient is Applied Therapeutics business performance
The return on equity has surged by 95% year-on-year and by 51% since the previous quarter
The return on assets has surged by 82% year-on-year and by 48% since the previous quarter
The company's return on sales rose by 30% QoQ
Dividends
What is APLT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APLT.
Financial health
How did Applied Therapeutics financials performed over time
The company's total assets is 181% higher than its total liabilities
The total liabilities has plunged by 76% YoY and by 32% from the previous quarter
The current ratio has soared by 67% YoY
APLT's debt is 93% smaller than its equity
The equity has declined by 46% year-on-year and by 36% since the previous quarter
The company's debt to equity rose by 40% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.